Skip to content

A study on siddha medicine "Swasakudori Chenduram" for"Silathuma kaasam"(Humid asthma)

A Clinical study on siddha Herbomineral Formulation "Swasakudori Chenduram"in "Silathuma kaasam"(Humid asthma)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026643
Enrollment
10
Registered
2020-07-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J00-J99- Diseases of the respiratory system

Interventions

Intervention1: Swasakudori chenduram: Single arm study Control Intervention1: Swasakudori chenduram: 2 arise (130 mg) two times a day (after food)(Internal) for 3 days

Sponsors

Ayothidoss Pandithar Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age 19 to 60 years 2.Sex: female, male, Transgender 3.Moderate persistent type of Bronchial Asthma 4.Weekly twice or daily symptoms of difficulty in breathing, Tightness of chest, Wheeze - Added sound (Rhonchi), cough with or without expectoration 5.FEV1/FVC reduced 5 percentage 6.Exacerbation is two or more in a year 7.Night time wheezing more than one day/week. 8.Obstructive type of asthma 9.Reversible by bronchodilators. 10.Asthma sometimes interferes with normal daily activities. 11.Patient who are willing to take radiological investigation and provide blood for lab investigation. 12.Patient who is willing to estimate volume of air forcibly expired after a deep inspiration by using Pulmonary Function Test.

Exclusion criteria

Exclusion criteria: 1.Restrictive lung disease 2.Tuberculosis 3.COPD 4.Lung Carcinoma and other Carcinomas 5.Status asthmatics 6.Emphysema 7.Pleural effusion 8.Cardiac disease 9.Hypertension 10.Renal disease 11.Diabetic mellitus 12.Recent abdominal, thoracic, or eye surgery 13.Symptoms of acute severe illness like Chest pain, nausea, vomiting, high fever, dyspnea 14.Recent hemoptysis 15.Pneumothorax 16.Recent history of abdominal, thoracic, or cerebral aneurysm 17.Sleep apnoea 18.Pregnancy 19.Lactation 20.Psychological factor

Design outcomes

Primary

MeasureTime frame
Primary outcome is assessed by comparing the lung volumes and capacities in pre and post treatment pulmonary function test. Timepoint: 6 months

Secondary

MeasureTime frame
1.Secondary outcome is assessed by comparing the parameters, before and after treatment 2.Relieving of other clinical symptoms. 3.Evaluating clinical lab parameters including ,AEC. Timepoint: 6 months

Countries

India

Contacts

Public ContactSathesh kumar M K

National Institute of Siddha

drlakshmiramaswamy@gmail.com09659327457

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026